Filtered By:
Condition: Ischemic Stroke
Nutrition: Sodium
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 297 results found since Jan 2013.
Sodium tanshinone IIA sulfonate ameliorates cerebral ischemic injury through regulation of angiogenesis
In conclusion, STS protected against ischemic brain injury by promoting angiogenesis in ischemic areas and inhibiting neuronal apoptosis. These results provide a potential treatment for stroke recovery.PMID:34504576 | PMC:PMC8383733 | DOI:10.3892/etm.2021.10556
Source: Experimental and Therapeutic Medicine - September 10, 2021 Category: General Medicine Authors: Jiazhen Xu Pei Zhang Yao Chen Yulan Xu Pengwei Luan Yuying Zhu Jiange Zhang Source Type: research
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Neuronal Swelling: A Non-osmotic Consequence of Spreading Depolarization
AbstractAn acute reduction in plasma osmolality causes rapid uptake of water by astrocytes but not by neurons, whereas both cell types swell as a consequence of lost blood flow (ischemia). Either hypoosmolality or ischemia can displace the brain downwards, potentially causing death. However, these disorders are fundamentally different at the cellular level. Astrocytes osmotically swell or shrink because they express functional water channels (aquaporins), whereas neurons lack functional aquaporins and thus maintain their volume. Yet both neuronsand astrocytes immediately swell when blood flow to the brain is compromised (c...
Source: Neurocritical Care - September 8, 2021 Category: Neurology Source Type: research
Characterization of Selenium Compounds for Anti-ferroptotic Activity in Neuronal Cells and After Cerebral Ischemia –Reperfusion Injury
AbstractThe emergence of ferroptosis as a cell death pathway associated with brain disorders including stroke and neurodegenerative diseases emphasizes the need to develop therapeutics able to target the brain and to protect neurons from ferroptotic death. Selenium plays an essential role in reducing lipid peroxidation generated during ferroptosis through its incorporation into the catalytic site of glutathione peroxidase 4. Here, we compared the anti-ferroptotic activity of several organic and inorganic selenium compounds: methylselenocysteine, selenocystine, selenomethionine, selenocystamine, ebselen, sodium selenite, an...
Source: Neurotherapeutics - September 8, 2021 Category: Neurology Source Type: research
Regional Differences in Early BP Management After Acute Ischemic Stroke in the ENCHANTED International Randomized Controlled Trials
Conclusion: Regional variations in early BP management in acute stroke translated into differences in early BP control parameters.
Source: Frontiers in Neurology - August 27, 2021 Category: Neurology Source Type: research
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Burden of cardiovascular disease from 1990 to 2017 in Henan Province, China
CONCLUSIONS: The absolute burden of CVDs in Henan is still high, although age-standardized DALYs declined between 1990 and 2017. The prevention and control of stroke and ischemic heart diseases should focus on a few modifiable risk factors which mainly contributed to the burden of CVDs, such as dietary factors, high systolic blood pressure, and tobacco use.PMID:34420496 | DOI:10.1080/16549716.2021.1959708
Source: Global Health Action - August 23, 2021 Category: International Medicine & Public Health Authors: Yan-Fang Zhao Tai Zhang Zhuo-Qun Wang Xiao-Rong Chen Chun-Xiao Wang Jin-Lei Qi Jing Yang Jing Wu Mai-Geng Zhou Source Type: research
Predicting 10-year stroke mortality: development and validation of a nomogram
AbstractPredicting long-term stroke mortality is a clinically important and unmet need. We aimed to develop and internally validate a 10-year ischaemic stroke mortality prediction score. In this UK cohort study, 10,366 patients with first-ever ischaemic stroke between January 2003 and December 2016 were followed up for a median (interquartile range) of 5.47 (2.96 –9.15) years. A Cox proportional-hazards model was used to predict 10-year post-admission mortality. The predictors associated with 10-year mortality included age, sex, Oxfordshire Community Stroke Project classification, estimated glomerular filtration rate (eG...
Source: Acta Neurologica Belgica - August 18, 2021 Category: Neurology Source Type: research
Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-Of-The-Art Review
Cardiovasc Hematol Agents Med Chem. 2021 Aug 9. doi: 10.2174/1871525719666210809121016. Online ahead of print.ABSTRACTSodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of anti-diabetic agents that block the reabsorption of glucose in the proximal convoluted tubule of the nephron, thereby contributing to glycosuria and lowering blood glucose levels. SGLT2 inhibitors have been associated with improved cardiovascular outcomes in patients with diabetes, including a reduced risk of cardiovascular death and hospitalizations for heart failure. Recently, DAPA-HF and EMPEROR REDUCED trials showed the beneficial cardiova...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - August 9, 2021 Category: Cardiology Authors: Mauro Gitto Dimitrios A Vrachatis Gianluigi Condorelli Konstantinos Papathanasiou Bernhard Reimers Spyridon Deftereos Giulio G Stefanini Source Type: research
